Introduction
It has been known for some time that regulation of the cyclic pattern of ovulation in female mammals involves the participa¬ tion of noradrenergic neurotransmitter mechanisms. In the hypothalamus, such neurotransmitter activity is a critical com¬ ponent of the sequence of events leading to the generation of the ovulatory surge of LH. Perturbations in this hypothalamic activity can suppress the midcycle increase in LH and block ovulation (Everett and Sawyer, 1950; Kalra and McCann, 1974; Goldman et al, 1994) . However, noradrenergic neuronal inner¬ vation is also present in the ovaries, suggesting that an alteration in noradrenergic activity by systemic xenobiotic exposure could affect the process of ovulation, not only by suppressing the LH surge, but also through a direct influence on the ovaries.
In mammals, noradrenergic sympathetic input reaches the ovary via the superior ovarian nerve and the nerves of the ovarian plexus that accompany the ovarian artery. In addition to this vascular innervation, catecholaminergic terminals have been identified histochemically within the stroma and follicular wall (Jacobowitz and Wallach, 1967) . There is evidence that this innervation is involved in the process of follicular maturation and ovulation, although the precise nature of this partici¬ pation has not been completely characterized. In prepubertal rats, peripheral noradrenergic depletion by multiple intraperitoneal injections of the adrenergic neurone blocking agent guanethidine delays vaginal opening and increases the number of oocytes detected at first ovulation (Flores et al, 1990) . A morphometric analysis of the ovaries from juveniles receiving guanethidine for 3 weeks beginning on day 7 after birth revealed a retardation of follicular development (Lara et al, 1990) . These (Curry et al, 1984) .
The purpose of the present study was to extend further the evidence for participation of such adrenergic mechanisms in the ovulatory process and to characterize those changes in the concentration of ovarian noradrenaline that could contribute to identifiable alterations in oocyte release. Normally cyclic, adult rats were given unilateral intrabursal injections of the noradrenergic neurotoxin N-(2-chloro-ethyI)-N-ethyl-2-bromobenzylamine (DSP4). This tertiary haloalkylamine derivative is both effective as a long-lasting inhibitor of the re-uptake of noradrenaline (Ross, 1973; Dudley et al, 1990) and can block the synthesis of noradrenaline by suppressing the activity of dopamine-ß-hydroxylase (Ross, 1976) . However, unlike 6-hydroxydopamine, these effects do not appear to be accompanied by nonspecific cellular damage (Dudley et al, 1990) or to cause alterations in dopamine (Ross, 1976; Lookingland et al, 1986) (Alden, 1942) . Although this foramen was reported to be functionally closed before ovulation (Alden, 1942) , its presence may explain contralateral alterations observed following such intrabursal administration (Reich et al, 1983 (Goldman and Cooper, 1993) Anterior and posterior hypothalamic regions were dissected and frozen as described previously (Goldman et al, 1994) .
Seven hours after the injection, portions of the somatosensory cortex were also taken for analysis, since cerebrocortical noradrenaline concentrations are affected markedly by systemic DSP4 administration (Jonsson et al, 1981; Lookingland et al, 1986 
Experiment 2
The effects of increasing doses of intrabursally administered DSP4 on ovarian noradrenaline are shown for injected and non-injected ovaries (Fig. 1) (Fig. 3) (Jacobson et al, 1985; Wilkinson et al, 1985) .
The discrepancy between oocyte release from the injected and non-injected ovaries, coincident with a comparable deple¬ tion in noradrenaline concentrations may indicate a distinction between the influence of DSP4 on metabolism of noradrenaline (in both ovaries) and some effect on noradrenergic input (of greater impact at the site of injection). This had previously been suggested to explain similar disparities between noradrenaline concentrations and DSP4 toxicity in the central nervous system (Gibson, 1987) . One possibility is that the ovarian neurotoxic effects of DSP4 at the site of injection involve an immune-mediated mechanism, something that has been described for guanethidine noradrenergic neurotoxicity (Manning et al, 1983) . Whether some compound-induced cytotoxic alterations did in fact occur over the [6] [7] [8] [9] [10] 
